Specifically, in pancreatic cancer, isolation yield and anti-PDAC reactivity of TILs (CD4+, CD8+) can be improved by adjuvant use of immune checkpoint blockade (PD-1). The gene discussed is CD8A; the disease is familial pancreatic carcinoma.